Alzheimer's Disease Research Center

阿尔茨海默病研究中心

基本信息

批准号：
10158691
负责人：
THOMAS M WISNIEWSKI
金额：
$ 42.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10158691
关键词：
Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Amyloid Area Autopsy Behavioral Biological Assay Biological Markers Cerebrospinal Fluid Clinical Clinical Data Cognitive Collaborations Communities Counseling Cyclotrons Data Linkages Data Set Dementia Development Diagnosis Diagnostic Services Early Diagnosis Education Fostering Funding Goals Health Heterogeneity Impaired cognition Infrastructure Intervention Investigation Laboratories Magnetic Resonance Imaging Measures Mental Depression Methodology Mission Neuropsychology New York Participant Pathology Patients Performance Phenotype Plasma Population Positron-Emission Tomography Proteomics Psychological Impact Radiochemistry Research Role Scanning Scientist Secure Statistical Data Interpretation Stress Techniques Therapeutic Intervention Time Training Training and Education Translational Research Treatment Efficacy Universities Update Work aged aging brain biomarker development cognitive function cognitive testing community setting data management disease heterogeneity education research epidemiology study improved in vivo induced pluripotent stem cell innovation mild cognitive impairment neuroimaging neuroimaging marker neuropathology next generation normal aging novel novel marker novel therapeutic intervention outreach posters prevent programs psychosocial recruit social factors sociodemographic variables tau Proteins

项目摘要

Since its inception in 1990, the Alzheimer's Disease Research Center (ADRC) at New York University Langone Health has facilitated pioneering research to define transitions from normal aging to the subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early dementia stages of AD; as well as AD biomarker development. Here we propose to continue this long-standing successful research direction with a focus on understanding disease heterogeneity and delineating biomarkers and their role in these transitions, with the long-term goal of helping to develop novel interventions that will delay or prevent cognitive decline. The NYU ADRC has built an infrastructure that supports innovative research on AD and related dementias (ADRD) to help achieve the NAPA goal of a cure by 2025. This will be facilitated by our nine highly successful and interactive Cores (Admin; Clinical; Data Management & Statistical [DMS]; Neuropathology; Outreach, Education & Engagement [ORE]; Neuroimaging; Biomarker; Psychosocial; and Research Education Component [REC]). Together, our highly integrated cores will achieve the following aims: Aim 1. Enhance the performance of innovative research in ADRC by maintaining nine cores that focus on delineating biomarkers of the transitions from normal aging to SCD, MCI, and early dementia, and determining their roles to help develop novel interventions that delay or prevent these transitions. We will also facilitate training in this area. Aim 2. Contribute to the national network of ADRCs by providing clinical data, autopsy diagnoses, neuroimaging and biosamples to NACC and NCRAD, as well as to other research community collaborative efforts in ADRD. Aim 3. Recruit and retain a diverse subject population from clinical and community settings, via the ORE and Psychosocial Cores, with concomitant engagement of the local scientific and lay community in ADRD with seminars, poster sessions and the developmental projects via the Admin, ORE, and REC Cores. Aim 4. Foster the development of novel avenues of investigation with methodological developments by the cores (via innovative cognitive assessments, neuroimaging techniques, biomarkers and proteomic approaches), and encourage, recruit, and select developmental projects. Aim 5. Accelerate translational research across the ADRD spectrum by using biomarkers to better define the underlying disease heterogeneity and foster the development of novel therapeutic interventions that consider this heterogeneity. Aim 6. Facilitate the education and training of a diverse ADRD workforce. Our Center will enhance the scientific community's understanding of ADRD and expand the next generation of diverse ADRD scientists, via combined efforts of the Admin, ORE, and REC Cores. In summary, the NYU ADRD has facilitated pioneering research that defined the stage transitions from normal aging to dementia, and contributed to AD biomarker development from its inception. In the next five years of funding, this focus will be expanded by: 1) improving our understanding of disease heterogeneity; 2) identifying new biomarkers that will allow early detection; and 3) fostering research that will develop effective therapeutic interventions.

自1990年成立以来，纽约大学Langone的阿尔茨海默氏病研究中心（ADRC）健康促进了开创性研究，以定义从正常衰老到主观认知的过渡衰落（SCD），轻度认知障碍（MCI）和AD的早期痴呆阶段；以及广告生物标志物发展。在这里，我们建议继续这个长期的成功研究方向，重点了解疾病异质性和描述生物标志物及其在这些过渡中的作用，有助于开发新的干预措施的长期目标，这些干预措施将延迟或预防认知能力下降。纽约大学ADRC建立了一个基础设施，该基础设施支持广告和相关痴呆症的创新研究（ADRD）帮助到2025年实现NAPA的目标。和交互式核心（管理员；临床；数据管理和统计[DMS]；神经病理学；外展，教育与参与[矿石]；神经影像；生物标志物；社会心理；和研究教育部分 [rec]）。我们高度集成的核心将共同实现以下目的：目标1。提高性能通过维护九个核心，专注于描述过渡的生物标志物的九个核心。从正常衰老到SCD，MCI和早期痴呆，并确定其作用以帮助发展新颖延迟或阻止这些过渡的干预措施。我们还将促进该领域的培训。目标2。贡献通过提供临床数据，尸检，神经成像和生物样本，来到ADRC的国家网络 NACC和NCRAD以及ADRD的其他研究社区合作努力。目标3。招募和通过矿石和社会心理核心，保留来自临床和社区环境中不同的受试者人群随着当地科学和外行社区与研讨会的互动，海报会议以及通过管理员，矿石和核心核心的发展项目。目标4。促进小说的发展核心的方法论发展途径（通过创新的认知评估，神经影像学技术，生物标志物和蛋白质组学方法），并鼓励，招募和选择发展项目。 AIM 5。通过使用ADRD频谱的转化研究生物标志物更好地定义潜在疾病异质性并促进新型治疗的发展考虑这种异质性的干预措施。目标6。促进多样化的教育和培训劳动力。我们的中心将增强科学界对ADRD的理解，并扩大下一个通过管理，矿石和核心的共同努力，产生了不同的ADRD科学家。总之， NYU ADRD促进了开创性研究，该研究定义了从正常衰老到的阶段过渡痴呆症，并从其成立开始为AD生物标志物的发展做出了贡献。在接下来的五年资金中，将通过以下方式扩大重点：1）提高我们对疾病异质性的理解； 2）识别新的生物标志物这将允许尽早发现； 3）促进将开发有效治疗干预措施的研究。